> Though substantial progress was being made, Pfizer decided to pull support ... [t]he “gliptin” class of drugs peaked at annual revenues of around $10 billion and remains a major oral therapy for type 2 diabetes.
> Even the biggest blockbusters can be dismissed ... by ... ambitious people, ... because ... ideas of how the market will react... .
> These same dynamics are undoubtedly playing out today [seemingly referring to previous statements on their COVID-19 vaccine], and it will likely take decades to determine just how costly some of today’s mistakes will prove to be.
Sure, a disease that kills a patient very quickly is bad for business. Better for them to be alive and fall ill later on from a laundry list of profitable ailments.